相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
K Wyatt et al.
HEALTH TECHNOLOGY ASSESSMENT (2014)
Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis
Saskia M. Rombach et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2014)
Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications
F. Weidemann et al.
JOURNAL OF INTERNAL MEDICINE (2013)
Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease
Camilla Tondel et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
Saskia M. Rombach et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis
Taciane Alegra et al.
GENETICS AND MOLECULAR BIOLOGY (2012)
Enzyme replacement therapy improves cardiac features and severity of Fabry disease
Manish Motwani et al.
MOLECULAR GENETICS AND METABOLISM (2012)
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation
David G. Warnock et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease: Natural History Data from the Fabry Registry
Christoph Wanner et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Four-Year Prospective Clinical Trial of Agalsidase Alfa in Children with Fabry Disease
Raphael Schiffmann et al.
JOURNAL OF PEDIATRICS (2010)
Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy Evidence for a Better Outcome With Early Treatment
Frank Weidemann et al.
CIRCULATION (2009)
New Equations to Estimate GFR in Children with CKD
George J. Schwartz et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data
A. Mehta et al.
LANCET (2009)
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
Raphael Schiffmann et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Stroke in Fabry Disease Frequently Occurs Before Diagnosis and in the Absence of Other Clinical Events Natural History Data From the Fabry Registry
Katherine Sims et al.
STROKE (2009)
Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa
D. A. Hughes et al.
HEART (2008)
Safety and efficacy of enzyme replacement therapy with agalsidase beta: An international, open-label study in pediatric patients with Fabry disease
J. Edmond Wraith et al.
JOURNAL OF PEDIATRICS (2008)
Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
William R. Wilcox et al.
MOLECULAR GENETICS AND METABOLISM (2008)
Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg
Anouk C. Vedder et al.
PLOS ONE (2007)
Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy - A retrospective analysis from the Fabry outcome survey
Bjoern Hoffmann et al.
CLINICAL JOURNAL OF PAIN (2007)
Sustained, long-term renal stabilization after 54 months of agalsidase β therapy in patients with Fabry disease
Dominique P. Germain et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Agalsidase-beta therapy for advanced Fabry disease - A randomized trial
Maryam Banikazemi et al.
ANNALS OF INTERNAL MEDICINE (2007)
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2006)
Medical progress - Assessing kidney function - Measured and estimated glomerular filtration rate
Lesley A. Stevens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Recommendations for chamber quantification
Roberto M. Lang et al.
EUROPEAN JOURNAL OF ECHOCARDIOGRAPHY (2006)
Natural history of the cerebrovascular complications of Fabry disease
A Mehta et al.
ACTA PAEDIATRICA (2005)
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey
A Mehta et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
Effect of enzyme-replacement therapy on gastrointestinal symptoms in Fabry disease
B Hoffmann et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2004)
Long-term safety and efficacy of enzyme replacement therapy for Fabry disease
WR Wilcox et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Fabry disease: overall effects of agalsidase alfa treatment
M Beck et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
Hearing loss in Fabry disease: The effect of agalsidase alfa replacement therapy
D Hajioff et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2003)
Enzyme replacement therapy in Fabry disease - A randomized controlled trial
R Schiffmann et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies
CM Eng et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
分享论文
